Across TCGA pan-cancer cohorts, CYP2B6 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP2B6 data layer compared with 14 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CYP2B6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CYP2B6 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, BRCA, and BLCA are the cancer types where CYP2B6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.059	0.772	<.001	24	view →
BRCA	OS	Median	All	0.193	0.580	.003	12	view →
BLCA	OS	Median	III,IV	0.149	0.581	.020	9	view →
STAD	DFS	Median	All	0.211	0.709	.015	3	view →
SKCM	OS	Median	III,IV	0.945	0.683	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: CYP2B6 tumor-vs-normal RNA expression · all CYP2B6 data types